Albany Molecular Research (Albany Molecular Research) Change In Working Capital : $-5.5 Mil (TTM As of Jun. 2017)

View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research Change In Working Capital?

Albany Molecular Research's change in working capital for the quarter that ended in Jun. 2017 was $4.1 Mil.

Albany Molecular Research's change in working capital for the fiscal year that ended in Dec. 2016 was $15.0 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Albany Molecular Research Change In Working Capital Historical Data

The historical data trend for Albany Molecular Research's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research Change In Working Capital Chart

Albany Molecular Research Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Change In Working Capital

Get a 7-Day Free Trial

-11.70

-4.33

-28.64

-0.60

14.97

Albany Molecular Research Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
Change In Working Capital	Get a 7-Day Free Trial															-2.39	6.24	5.05	-20.82	4.06

Albany Molecular Research Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.5 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Albany Molecular Research Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Albany Molecular Research (Albany Molecular Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.amriglobal.com

Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.

Executives

Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin	officer: SVP, Treasurer & CFO	26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming	director	C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth	director, officer: President and CEO	236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson	officer: SVP, Secretary & Gen Counsel	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung	director	C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther	officer: Senior VP, Discovery Services	21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost	officer: Chief Financial Officer	21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek	officer: Chief Financial Officer	ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines